Join us on Wednesday, August 5 for the live webinar
5:00 PM – 6:30 PM ET
1.5 AMA PRA Category 1 Credits^TM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Lilly and Merck.

Current and Emerging Paradigm for the Treatment of Small Cell Lung Cancer (SCLC) — David R Spigel, MD

• Designs, eligibility criteria and key efficacy and safety findings from the pivotal Phase III IMpower133 and CASPIAN trials evaluating atezolizumab or durvalumab, respectively, in combination with chemotherapy for patients with previously untreated extensive-stage SCLC
• FDA approvals of first-line carboplatin/etoposide/atezolizumab and platinum/etoposide/durvalumab and appropriate integration into current extensive-stage SCLC management
• Available clinical trial data with and current clinical role of anti-PD-1/PD-L1 antibodies alone or in combination with anti-CTLA-4 antibodies for progressive SCLC
• Mechanism of action of lurbinectedin; design, eligibility criteria and major efficacy and safety findings of the Phase II basket trial assessing lurbinectedin for patients with SCLC that has progressed after prior platinum-based therapy; recent FDA approval and integration into the treatment algorithm
• Other novel agents and strategies under investigation for patients with extensive- and limited-stage SCLC

Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Stephen V Liu, MD, PhD

• Design of, eligibility criteria for and key efficacy and safety findings from the Phase III PACIFIC trial evaluating the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
• Role of durvalumab consolidation in patients with locally advanced NSCLC and low PD-L1 expression or targetable genomic alterations
• Rates of Grade 3 and 4 adverse events, including pneumonitis and other immune-mediated events, and treatment discontinuation among patients receiving durvalumab in the PACIFIC study
• Available results from the Phase II KEYNOTE-799 trial evaluating pembrolizumab in combination with concurrent chemoradiation therapy in untreated patients with unresectable, locally advanced NSCLC
• Ongoing and planned clinical trial strategies with immune checkpoint inhibitors in nonmetastatic NSCLC

Long-Term Management of Metastatic NSCLC without a Targetable Tumor Mutation — Edward B Garon, MD, MS

• Clinical trial database supporting the FDA approvals of up-front anti-PD-1/PD-L1 monotherapy (pembrolizumab, atezolizumab) and combined chemotherapy/immune checkpoint inhibition (pembrolizumab/chemotherapy, atezolizumab/chemotherapy with or without bevacizumab) in metastatic NSCLC; role of PD-L1 expression and TMB in therapeutic decision-making
• Phase III clinical trial results (CheckMate 227, CheckMate 9LA) leading to the recent FDA approvals of first-line nivolumab/ipilimumab with and without chemotherapy in metastatic NSCLC; optimal integration into routine practice
• Design, eligibility criteria and emerging safety and efficacy data from the Phase III POSEIDON trial evaluating durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line therapy for patients with metastatic NSCLC
• Mechanism of action of tiragolumab and biologic rationale for combining it with anti-PD-L1 immunotherapy; results from the Phase II CITYSCAPE trial evaluating tiragolumab with atezolizumab as first-line therapy for patients with locally advanced or metastatic NSCLC
• Management of disease that has progressed on anti-PD-1/PD-L1-based therapy in the first-line setting; current role of approved agents and regimens (ramucirumab, afatinib, bevacizumab, et cetera)

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives

• Use available clinical trial findings and evidence-based guidelines to inform the use of immune checkpoint inhibitors alone or in combination with chemotherapy for patients with extensive-stage small cell lung cancer (SCLC).
• Assess clinical trial data leading to the recent FDA approval of lurbinectedin for patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy, and identify individuals for whom treatment with this novel agent may be appropriate.
• Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
• Formulate treatment strategies to appropriately incorporate the use of anti-PD-1/ PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for newly diagnosed metastatic NSCLC.
• Evaluate the benefits and risks of anti-PD-1/ PD-L1 and anti-CTLA-4 antibody combinations with or without chemotherapy as first-line treatment for NSCLC, and determine which patients may be most appropriate for this treatment approach.
• Develop management strategies for NSCLC that relapses after initial treatment with anti-PD-1/PD-L1 antibody therapy, considering guideline recommendations for appropriate therapeutic options.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Garon — Advisory Committee: Dracen Pharmaceuticals, EMD Serono Inc, GlaxoSmithKline, Mirati Therapeutics, Novartis; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis. Dr Liu — Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc, Takeda Oncology; Contracted Research: Alkermes, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Lycera, Merck, Merus BV, Molecular Partners, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Spectrum Pharmaceuticals Inc, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Taiho Oncology Inc. Dr Spigel — Consulting Agreements: Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dracen Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Iksuda Therapeutics, Illumina, Merck, Molecular Templates, Nektar, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Seattle Genetics, Takeda Pharmaceutical Company Limited, Triptych Health Partners, TRM Oncology; Contracted Research: Aeglea BioTherapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BIND Therapeutics Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, G1 Therapeutics, Genentech, a member of the Roche Group, GRAIL, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Molecular Partners, Nektar, Neon Therapeutics, Novartis, Takeda Oncology, Transgene, UT Southwestern Medical Center.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Lilly and Merck.